Trials / Completed
CompletedNCT00652782
Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients
A Randomized, Double-Blind, Placebo Controlled Dose-Ranging Study of The Effects of MK7418, Both as Monotherapy and in Combination With Furosemide, On Diuresis and Renal Function in Patients With Congestive Heart Failure (CHF) And Renal Impairment Treated With Oral Loop Diuretics Who Require Hospitalization For Fluid Overload
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study to determine the most appropriate dose of MK7418 in heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rolofyline | rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days |
| DRUG | Comparator Placebo (unspecified) | Matching placebo for rolofyline IV QD; 3 days |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2005-08-01
- First posted
- 2008-04-04
- Last updated
- 2008-04-04
Source: ClinicalTrials.gov record NCT00652782. Inclusion in this directory is not an endorsement.